Phân Tích Sinh Học Phân Tử Của Các Tế Bào CD34+ Trong Bệnh U Tủy Xương Tự Phát Nhận Diện Một Tập Hợp Các Gen Liên Quan Đến Bệnh Và Tiết Lộ Ý Nghĩa Lâm Sàng Của Gen U Wilms 1 (WT1)

Vardiman, 2002, The World Health Organization (WHO) classification of the myeloid neoplasms, Blood, 100, 2292, 10.1182/blood-2002-04-1199

Barosi, 1999, Myelofibrosis with myeloid metaplasia: Diagnostic definition and prognostic classification for clinical studies and treatment guidelines, J Clin Oncol, 17, 2954, 10.1200/JCO.1999.17.9.2954

Tefferi, 2000, Myelofibrosis with myeloid metaplasia, N Engl J Med, 342, 1255, 10.1056/NEJM200004273421706

Xu, 2005, The constitutive mobilization of bone marrow-repopulating cells into the peripheral blood in idiopathic myelofibrosis, Blood, 105, 1699, 10.1182/blood-2004-06-2485

Xu, 2005, The constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases, Blood, 105, 4508, 10.1182/blood-2004-08-3238

Barosi, 2001, Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia, Blood, 98, 3249, 10.1182/blood.V98.12.3249

Arora, 2005, Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia: A prospective evaluation of prognostic value in 94 patients, Br J Haematol, 128, 42, 10.1111/j.1365-2141.2004.05280.x

Mesa, 2005, Leukemic transformation in myelofibrosis with myeloid metaplasia: A single-institution experience with 91 cases, Blood, 105, 973, 10.1182/blood-2004-07-2864

Castro-Malaspina, 1984, Properties of myelofibrosis-derived fibroblasts, Prog Clin Biol Res, 154, 307

Le Bousse-Kerdiles, 2001, Involvement of the fibrogenic cytokines, TGF-beta and bFGF, in the pathogenesis of idiopathic myelofibrosis, Pathol Biol (Paris), 49, 153, 10.1016/S0369-8114(00)00021-3

Villeval, 1997, High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice, Blood, 90, 4369, 10.1182/blood.V90.11.4369

Yan, 1996, A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand): Reversal of disease by bone marrow transplantation, Blood, 88, 402, 10.1182/blood.V88.2.402.bloodjournal882402

Vannucchi, 2002, Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1(low) mice), Blood, 100, 1123, 10.1182/blood-2002-06-1913

Pikman, 2006, MPLW515L Is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia, PLoS Med, 3, e270, 10.1371/journal.pmed.0030270

Vannucchi, 2005, Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis, Am J Pathol, 167, 849, 10.1016/S0002-9440(10)62056-1

Levine, 2005, Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis, Cancer Cell, 7, 387, 10.1016/j.ccr.2005.03.023

Baxter, 2005, Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders, Lancet, 365, 1054, 10.1016/S0140-6736(05)71142-9

James, 2005, A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera, Nature, 434, 1144, 10.1038/nature03546

Kralovics, 2005, A gain-of-function mutation of JAK2 in myeloproliferative disorders, N Engl J Med, 352, 1779, 10.1056/NEJMoa051113

Lippert, 2006, The JAK2–V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera, Blood, 108, 1865, 10.1182/blood-2006-01-013540

Antonioli, 2005, Clinical implications of the JAK2 V617F mutation in essential thrombocythemia, Leukemia, 19, 1847, 10.1038/sj.leu.2403902

Lacout, 2006, JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis, Blood, 108, 1652, 10.1182/blood-2006-02-002030

Wernig, 2006, Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model, Blood, 107, 4274, 10.1182/blood-2005-12-4824

Cazzola, 2005, Gain of function, loss of control - a molecular basis for chronic myeloproliferative disorders, Haematologica, 90, 871

Kaushansky, 2005, On the molecular origins of the chronic myeloproliferative disorders: It all makes sense, Blood, 105, 4187, 10.1182/blood-2005-03-1287

Ebert, 2004, Genomic approaches to hematologic malignancies, Blood, 104, 923, 10.1182/blood-2004-01-0274

Bilhou-Nabera, 2003, Does cytogenetic mosaicism in CD34+CD38low cells reflect the persistence of normal primitive hematopoietic progenitors in myeloid metaplasia with myelofibrosis?, Blood, 102, 1551, 10.1182/blood-2003-03-0691

Barosi, 1999, The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia, Br J Haematol, 104, 730, 10.1046/j.1365-2141.1999.01262.x

Dupriez, 1996, Prognostic factors in agnogenic myeloid metaplasia: A report on 195 cases with a new scoring system, Blood, 88, 1013, 10.1182/blood.V88.3.1013.1013

Marchetti, 2004, Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: A phase II trial, J Clin Oncol, 22, 424, 10.1200/JCO.2004.08.160

Keeney, 1998, Single platform flow cytometric absolute CD34+ cell counts based on the ISHAGE guidelines. International Society of Hematotherapy and Graft Engineering, Cytometry, 34, 61, 10.1002/(SICI)1097-0320(19980415)34:2<61::AID-CYTO1>3.0.CO;2-F

Manfredini, 2005, The kinetic status of hematopoietic stem cell subpopulations underlies a differential expression of genes involved in self-renewal, commitment, and engraftment, Stem Cells, 23, 496, 10.1634/stemcells.2004-0265

Boucheix, 2001, Tetraspanins, Cell Mol Life Sci, 58, 1189, 10.1007/PL00000933

Zannettino, 1998, The sialomucin CD164 (MGC-24v) is an adhesive glycoprotein expressed by human hematopoietic progenitors and bone marrow stromal cells that serves as a potent negative regulator of hematopoiesis, Blood, 92, 2613, 10.1182/blood.V92.8.2613

Burger, 2006, CXCR4: A key receptor in the crosstalk between tumor cells and their microenvironment, Blood, 107, 1761, 10.1182/blood-2005-08-3182

Steidl, 2002, Gene expression profiling identifies significant differences between the molecular phenotypes of bone marrow-derived and circulating human CD34+ hematopoietic stem cells, Blood, 99, 2037, 10.1182/blood.V99.6.2037

Clay, 2001, CD9 and megakaryocyte differentiation, Blood, 97, 1982, 10.1182/blood.V97.7.1982

Jones, 2005, Detection of aberrant gene expression in CD34+ hematopoietic stem cells from patients with agnogenic myeloid metaplasia using oligonucleotide microarrays, Stem Cells, 23, 631, 10.1634/stemcells.2004-0131

Nelson, 2004, Convergence of Wnt, beta-catenin, and cadherin pathways, Science, 303, 1483, 10.1126/science.1094291

Falanga, 2005, Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: The role of neutrophils, Semin Hematol, 42, 239, 10.1053/j.seminhematol.2005.05.023

Gene Expression Omnibus profiles

Tefferi, 2005, Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia, Br J Haematol, 131, 166, 10.1111/j.1365-2141.2005.05743.x

Goerttler, 2005, The Jak2V617F mutation, PRV-1 overexpression and EEC formation define a similar cohort of MPD patients, Blood, 106, 2862, 10.1182/blood-2005-04-1515

Kralovics, 2005, Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2, Blood, 106, 3374, 10.1182/blood-2005-05-1889

Keilholz, 2005, Wilms' tumour gene 1 (WT1) in human neoplasia, Leukemia, 19, 1318, 10.1038/sj.leu.2403817

Cilloni, 2003, Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes, J Clin Oncol, 21, 1988, 10.1200/JCO.2003.10.503

Inoue, 1994, WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia, Blood, 84, 3071, 10.1182/blood.V84.9.3071.3071

Inoue, 1998, Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells, Blood, 91, 2969, 10.1182/blood.V91.8.2969.2969_2969_2976

Tsuboi, 1999, Constitutive expression of the Wilms' tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor (G-CSF), Leuk Res, 23, 499, 10.1016/S0145-2126(99)00037-5

Jomgeow, 2006, Wilms' tumor gene WT1 17AA(-)/KTS(-) isoform induces morphological changes and promotes cell migration and invasion in vitro, Cancer Sci, 97, 259, 10.1111/j.1349-7006.2006.00169.x

Sakajiri, 2005, Dlk1 in normal and abnormal hematopoiesis, Leukemia, 19, 1404, 10.1038/sj.leu.2403832

Miyazato, 2001, Identification of myelodysplastic syndrome-specific genes by DNA microarray analysis with purified hematopoietic stem cell fraction, Blood, 98, 422, 10.1182/blood.V98.2.422

Huang, 2004, The human Delta-like 1 homologue is implicated in the progression of liver fibrosis in biliary atresia, J Pathol, 202, 172, 10.1002/path.1505

Oka, 2004, Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression, Proc Natl Acad Sci U S A, 101, 13885, 10.1073/pnas.0405884101

Barosi, 2005, Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET), Blood, 106, 2849, 10.1182/blood-2005-04-1520